Skip to main content
SpringerLink
Log in

Health Canada has informed Canadians of a possible link between Baraclude [entecavir] and the development of a treatment-resistant HIV strain

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Health Canada.Health Canada examining information linking antiviral drug to development of treatment-resistant HIV. Media Release: 21 Feb 2007. Available from: URL: http://www.hc-sc.gc.ca

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Health Canada has informed Canadians of a possible link between Baraclude [entecavir] and the development of a treatment-resistant HIV strain. React. Wkly. 1141, 2 (2007). https://doi.org/10.2165/00128415-200711410-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711410-00004

Keywords

Search

Navigation